Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week’s Business Updates

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has been making waves in the stock market recently, with its share price soaring to new heights. The company’s strong performance on Wednesday saw its stock price climb by 6.81 percent to close at $4.86 per share. Investors have been eagerly buying up shares in anticipation of upcoming business updates, as Recursion is set to participate in two major conferences next week.

In a recent statement, Recursion Pharmaceuticals announced that its president and CEO, Najat Khan, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, followed by the 28th Annual Needham Growth Conference on January 16. These events are expected to provide valuable insights into the company’s future plans and growth strategy.

Investors are particularly interested in hearing about Recursion’s earnings performance for 2025, updates on its pipeline, and its outlook for 2026. Last month, investment firm JPMorgan upgraded the stock to “overweight” from “neutral” and raised its price target to $11 from $10. This decision was based on positive results from the latest clinical trial of REC-4881, a therapy candidate aimed at treating Familial Adenomatous Polyposis.

JPMorgan believes that REC-4881 has the potential to generate $1 billion in sales in the United States, further boosting investor confidence in Recursion Pharmaceuticals. However, while RXRX remains a promising investment option, some experts suggest that other AI stocks may offer even greater returns with lower downside risk.

For investors looking for a budget-friendly AI stock with significant growth potential, there is a recommendation to check out a free report on the best short-term AI stock. This stock is positioned to benefit from Trump tariffs and onshoring initiatives, making it an attractive investment opportunity.

In conclusion, Recursion Pharmaceuticals’ recent performance and upcoming conferences have put the company in the spotlight. While RXRX continues to show promise, investors may want to explore other AI stocks for potentially higher returns. Stay tuned for updates on Recursion’s future developments and watch out for more investment opportunities in the rapidly evolving AI sector.

Disclosure: None. This article was originally published on Insider Monkey.